Current issues in GLP-1 receptor agonist therapy for type 2 diabetes

Endocrine Practice

Volumn 18, Issue SUPPL.3, 2012, Pages 6-26

  Bloomgarden, Zachary ^a   Blonde, Lawrence ^b   Garber, Alan ^c   Wysham, Carol ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; C REACTIVE PROTEIN; CALCITONIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE PANCREATITIS; ADIPOSE TISSUE; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; BONE; BRAIN; CALCITONIN BLOOD LEVEL; CARDIOVASCULAR RISK; DIABETIC DIET; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY FAILURE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PANCREATITIS; PATIENT PREFERENCE; SIDE EFFECT; STOMACH; STOMACH EMPTYING; THYROID MEDULLARY CARCINOMA; VOMITING; WEIGHT REDUCTION;

EID: 84872335789     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12300.RA     Document Type: Article

References (212)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.
2. Asmar M, Holst JJ. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr Opin Endocrinol Diabetes Obes. 2010;17:57-62.
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-307.
4. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
5. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205-211.
6. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39:1546-1553.
7. U.S. National Institutes of Health. ClinicalTrials.gov: a service of the U.S. National Institutes of Health. http://www.clinicaltrials.gov/ct2/home. Accessed for verification October 25, 2012.
8. Januvia (sitagliptin) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2010. http://www.merck.com/product/usa/pi-circulars/j/ januvia/januvia-pi.pdf. Accessed for verification October 25, 2012.
9. Onglyza (saxagliptin) [prescribing information]. Princeton, NJ, and Wilmington, DE: Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals LP; 2011. http://packageinserts.bms.com/pi/pi-onglyza. pdf. Accessed for verification October 25, 2012.
10. Tradjenta (linaglip) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2011. http://hcp. tradjenta.com/prescribinginformation.jsp. Accessed for verification October 25, 2012.
11. U.S. Food and Drug Administration. Sitagliptin (marketed as Januvia and Janumet) information. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm183768.htm. Accessed for verification October 25, 2012.
12. Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals [press release]. Basel, Switzerland: Novartis; January 18, 2012. http://www.novartis. com/newsroom/media-releases/en/2012/1578311.shtml. Accessed for verification October 25, 2012.
13. Launches of "NESINA®" for treatment of type 2 diabetes, "UNISA®" for treatment of hypertension, and "Vectibix® ", anti-cancer agent, in Japan [press release]. Osaka, Japan: Takeda Pharmaceutical Company Limited; June 15, 2012. http://www.takeda.com/press/ article-36506.html. Accessed for verification October 25, 2012.
14. LG's 'gemiglo' wins KFDA approval. The Korean Herald. June 28, 2012. http://view.koreaherald.com/kh/view. php?ud=20120628001086. Accessed for verification October 25, 2012.
15. Takeda receives complete response letter from the FDA for type 2 diabetes investigational therapies alogliptin and fixed-dose combination alogliptin and pioglitazone [press release]. Deerfield, IL: Takeda Pharmaceutical Company Limited; April 25, 2012. http://www.takeda.com/press/article-45508.html. Accessed for verification October 25, 2012.
16. Byetta (exenatide) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc.; 2011. http://documents.byetta.com/Byetta-PI.pdf. Accessed for verification October 25, 2012.
17. Victoza (liraglutide [rDNA] injection) [prescribing information]. Princeton, NJ: Novo Nordisk Inc.; 2012. http://www.novo-pi. com/victoza.pdf. Accessed for verification October 25, 2012.
18. Bydureon (exenatide extended-release for injectable suspension) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals Inc.; 2012. http://documents. bydureon.com/Bydureon-PI.pdf. Accessed for verification October 25, 2012.
19. Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14:161-168.
20. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943-2952.
21. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456.
22. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35:252-258.
23. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab. 2011;13:982-989.
24. Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397-407.
25. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431-439.
26. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003). 2009;49(Suppl 1):S16-S29.
27. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-1493.
28. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17(Suppl 2):1-53.
29. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35(Suppl 1):S11-S63.
30. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379.
31. Rodbard HW, Jellinger PS, Bloomgarden ZT, et al. Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
32. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
33. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1250.
34. Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301-1310.
35. Amylin Pharmaceuticals Inc. Study results - safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes. http://www.clinicaltrials.gov/ct2/show/NCT01029886?term=NCT01029886&ra nk=1. Accessed August 7, 2012.
36. Buse J, Nauck M, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. 47th Annual Meeting of the European Association for the Study of Diabetes; September 12-16, 2011; Lisbon, Portugal [abstract 75].
37. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300-1303.
38. Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33:1255-1261.
39. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-2348.
40. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
41. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab. 2009;11(12):1153-1162.
42. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
43. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569.
44. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
45. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460.
46. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-267.
47. Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477-485.
48. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
49. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
50. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84-90.
51. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.
52. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-1230.
53. Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label clinical trial of efficacy and safety in patients with type 2 diabetes inadequately controlled with metformin ± sulfonylureas. American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA [abstract 40-LB].
54. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234-2243.
55. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24:275-286.
56. Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:348-356.
57. MacConell L, Li Y, Pencek R, Schulteis C, Porter L. Exenatide once weekly resulted in sustained improvement in glycemic control with weight loss through 4 years. American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA [abstract 1156-P].
58. Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med. 2010;122:118-128.
59. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012;35:683-689.
60. Violante R, Oliveira JH, Yoon KH, et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med. 2012 Feb 29. [Epub ahead of print].
61. Mentis N, Vardarli I, Kothe LD, et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011;60:1270-1276.
62. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009;52:199-207.
63. Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: Analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124:21-32.
64. Pencek R, Blickensderfer A, Li Y, Brunell SC, Chen S. Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations. Int J Clin Pract. 2012 Aug 24. [Epub ahead of print]
65. Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract. 2012;18:227-237.
66. Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. Postgrad Med. 2012;124:33-40.
67. Garber A, Matthews D, Zinman B, Thomsen A, Flalhati A, Guerci B. The effect of disease stage, indicated by number of previous oral antidiabetic agents, on the response to liraglutide in type 2 diabetes. Diabetes. 2011;60(Suppl 1):0967-P.
68. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122(6 Suppl):S37-50.
69. Turner RC, Cull CA, Frighi V, Holman RR, United Kingdom Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
70. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
71. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
72. Thong K, Walton C, Ryder R, ABCD Nationwide Liraglutide Audit Contributors. Insulin necessity is better than diabetes duration in predicting liraglutide treatment response: The Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA [abstract 1038-P].
73. Kondo Y, Nagakura J, Kimura M, Satoh S. Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA [abstract 1005-P].
74. Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications. 2012 Aug 2. [Epub ahead of print].
75. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103-112.
76. DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35:1446-1454.
77. Bain SC, DeVries JH, Seufert J, et al. Adding insulin detemir (IDet) to liraglutide and metformin improves glycaemic control with sustained weight reduction and low hypoglycaemia rate: 52 week results. Diabetologia. 2011;54(Suppl 1):73.
78. Lane W, Weinrib S, Rappaport J. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes Technol Ther. 2011;13:592-595.
79. Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab. 2004;89:3469-3473.
80. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010;33:1294-1296.
81. Sarkar G, Alattar M, Brown R, Quon M, Harland D, Rother K. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes mellitus. American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA [abstract 12-OR].
82. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual {beta}-cell function. Diabetes Care. 2011;34:1463-1468.
83. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84.
84. Kuhadiya N, Malik R, Bellini N, et al. Long-term follow-up of patients with type 1 diabetes on lirglutide and the effect of liraglutide as additional treatment in obese patients with type 1 diabetes. Endocr Rev. 2012;33:OR17-1.
85. Nauck MA, Vardarli I. Genetic determinants predicting efficacy of glucose-lowering drugs?: a long way to go Diabetes Care. 2010;33:2123-2125.
86. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14:546-554.
87. Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96:1695-1702.
88. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50:65-74.
89. Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14:546-554.
90. Norman RA, Permana P, Tanizawa Y, Ravussin E. Absence of genetic variation in some obesity candidate genes (GLP1R, ASIP, MC4R, MC5R) among Pima Indians. Int J Obes Relat Metab Disord. 1999;23:163-165.
91. Tanizawa Y, Riggs AC, Elbein SC, Whelan A, Donis-Keller H, Permutt MA. Human glucagon-like peptide-1 receptor gene in NIDDM. Identification and use of simple sequence repeat polymorphisms in genetic analysis. Diabetes. 1994;43:752-757.
92. Yagi T, Nishi S, Hinata S, Murakami M, Yoshimi T. A population association study of four candidate genes (hexokinase II, glucagon-like peptide-1 receptor, fatty acid binding protein-2, and apolipoprotein C-II) with type 2 diabetes and impaired glucose tolerance in Japanese subjects. Diabet Med. 1996;13:902-907.
93. Beinborn M, Worrall CI, McBride EW, Kopin AS. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept. 2005;130:1-6.
94. Sathananthan A, Man CD, Micheletto F, et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care. 2010;33:2074-2076.
95. Koole C, Wootten D, Simms J, et al. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: Allosteric rescue of loss of function mutation. Mol Pharmacol. 2011;80:486-497.
96. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - The FDA's review of a new antidiabetic therapy. N Engl J Med. 2010;362:774-777.
97. U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products. http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/. Accessed August 19, 2012.
98. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473-1486.
99. Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153:1538-1547.
100. Gier B, Butler PC, Lai CK, Kirakossian D, Denicola MM, Yeh MW. Glucagon-like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121-131.
101. Waser B, Beetschen K, Pellegata NS, Reubi JC. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: Relevance for incretin-based diabetes therapy. Neuroendocrinology. 2011;94(4):291-301.
102. National Cancer Institute. Thyroid cancer treatment (PDQ): general information about thyroid cancer. http://www.cancer.gov/cancertopics/pdq/ treatment/thyroid/HealthProfessional. Accessed for verification October 25, 2012.
103. U.S. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. FDA briefing materials- liraglutide. http://www.fda.gov/ ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf. Accessed for verification October 25, 2012.
104. U.S. Food and Drug Administration. Endocrine and Metabolics Drugs Advisory Committee Panel. FDA briefing document: NDA 202293: Dapagliflozin tablets, 5 and 10 mg. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeeting Materials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/UCM262994.pdf. Accessed for verification October 25, 2012.
105. Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96:853-860.
106. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156.
107. U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS) (formerly AERS). http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default. htm. Accessed for verification October 25, 2012.
108. European Association for the Study of Diabetes. EASD commentary on the publication by Elashoff et al., published online in gastroenterology, February 2011: increased incidence of pancreatitis and cancer among patients given glucagon-like peptide-1- based therapy. http://87.234.226.93/easd-intranet/ easdwebfiles/statements/Elashoff-Commentary.pdf. Accessed for verification October 25, 2012.
109. U.S. Food and Drug Administration. Victoza NDA approval letter. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2010/022341s000ltr. pdf. Accessed for verification October 25, 2012.
110. U.S. Food and Drug Administration. Bydureon NDA approval letter. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2012/022200s000ltr.pdf. Accessed for verification October 25, 2012.
111. Novo Nordisk. Important drug warning concerning Victoza®. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHuman MedicalProducts/UCM258828.pdf. Accessed for verification October 25, 2012.
112. Amylin Pharmaceuticals Inc. Important drug warning. http://bydureonhcp. com/Content/pdf/Dear-HCP-Letter.pdf. Accessed for verification October 25, 2012.
113. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834-838.
114. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab. 2010;12:766-771.
115. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349- 2354.
116. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-1027.
117. Wenten M, Gaebler J, Hussein M, et al. A retrospective cohort study to assess the relative risk of acute pancreatitis among initiators of exenatide compared to initiators of other antidiabetic medication: A follow-up study. Diabetes. 2010;59(Suppl 1):A163.
118. Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab. 2011;13:559-566.
119. Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med. 2012 Mar 14. [Epub ahead of print].
120. Romley JA, Goldman DP, Solomon M, McFadden D, Peters AL. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Ther. 2012 Jul 30. [Epub ahead of print].
121. Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. 2011 Oct 19. [Epub ahead of print].
122. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab. 2011;96:2027-2031.
123. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33:428-433.
124. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the kras (G12D) mouse model. Diabetes. 2012;61:1250-1262.
125. Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes. 2012;61:1243-1249.
126. Tuttle K, Brown C, Lee D, et al. Effect of exenatide BID on kidney function and adverse events in clinical trials. Diabetes. 2011;60(Suppl 1):971-P.
127. Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab. 2012;14:596-600.
128. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract. 2011;17:345-355.
129. Macconell L, Brown C, Gurney K, Han J. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes. 2012;5:29-41.
130. MacConell L, Gurney K, Malloy J, Zhang H, Zhou M, Chen S. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4328 patients. American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA [abstract 2372-PO].
131. Johansen OE, Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol. 2008;66:568-569.
132. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32:e22-23.
133. Ferrer-Garcia J, Martinez-Chanza N, Tolosa-Torrens M, Sanchez-Juan C. Exenatide and renal failure. Diabetic Med.;27:728-729.
134. Lopez-Ruiz A, del Peso-Gilsanz C, Meoro- Aviles A, et al. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers. Pharm World Sci. 2010;32:559-561.
135. Kaakeh Y, Kanjee S, Boone K, Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy. 2012;32:e7-11.
136. Nandakoban H, Furlong TJ, Flack Jr. Acute tubulointerstitial nephritis following treatment with exenatide. Diabet Med. 2012 Jul 4. [Epub ahead of print].
137. Bhatti R, Flynn M, Illahi M, Carnegie A. Exenatide associated renal failure. Pract Diabetes Int. 2010;27:232-234.
138. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317-327.
139. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68:898-905.
140. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: An integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
141. Marso SP, Lindsey JB, Stolker JM, et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies. Diab Vasc Dis Res. 2011;8:237-240.
142. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease
143. Best JH, Little W, Chiquette E, Saunders WB, Maggs D. The risk of heart failure among patients receiving exenatide versus other glucose-lowering medications for type 2 diabetes: a matched retrospective cohort analysis of the GE healthcare electronic medical record database. Diabetes. 2011;60(Suppl 1):1133-P.
144. Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol. 2009;49:1353-1362.
145. Linnebjerg H, Seger M, Kothare PA, Hunt T, Wolka AM, Mitchell MI. A thorough QT study to evaluate the effects of single dose exenatide 10 mug on cardiac repolarization in healthy subjects. Int J Clin Pharmacol Ther. 2011;49:594-604.
146. Sager P, Darpö B, Han J, et al. Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes. Diabetes. 2011;60(Suppl 1):1070-P.
147. Darpo B, Sager P, Macconell L, et al. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol. 2012 Aug 10. [Epub ahead of print].
148. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
149. Fonseca V, Plutzky J, Montanya E, et al. Liraglutide, a once-daily human GLP-1 analog, lowers systolic blood pressure (SBP) independently of concomitant antihypertensive treatment. Diabetes. 2010;59(Suppl 1):A79.
150. Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9:209-222.
151. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444-450.
152. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23:334-339.
153. Paul S, Best J, Klein K, Han J, Maggs D. Effects of HbA(1c) and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide. Diabetes Obes Metab. 2012;14:826-834.
154. Xiao C, Bandsma R, Dash S, Szeto L, Lewis G. Exenatide, a glucagon-like peptide receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. 2012;32:1513-1519.
155. Hermansen K, Baekdal T, During M, et al. Liraglutide suppresses postprandial triglyceride (TG) and apolipoprotein B48 (ApoB48) responses to a fat-rich meal in subjects with type 2 diabetes. Canadian J Diabetes. 2012;36(5):S35.
156. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681.
157. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet. 2010;375:1875-1884.
158. Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol. 2009;55:42-44.
159. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
160. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med. 2011;365:2255-2267.
161. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: Extending treatment beyond statins in the high-risk cardiovascular patient. Heart. 2011;9:350-356.
162. Duckworth WC, Abraira C, Moritz T, VADT Investigators. VA diabetes trial (VADT) update. http://webcasts.prous.com/netadmin/webcast-viewer/Preview.aspx: type=0&lid=9473&pv=2&preview=False&id cl=0. Accessed for verification October 25, 2012.
163. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-1418.
164. Zoungas S, de Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009;32:2068-2074.
165. Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379:2270-2278.
166. Bunck MC, Diamant M, Eliasson B, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33:1734-1737.
167. Derosa G, Putignano P, Bossi AC, et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol. 2011;666:251-256.
168. Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent anti-inflammatory effect J Clin Endocrinol Metab. 2012;97:198-207.
169. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Katz H, Bank AJ. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012;11:64.
170. Kelly A, Metzig A, Rudser K, et al. Exenatide as a weight-loss therapy in extremely obese youth without diabetes. Diabetes. 2011;60(Suppl 1):420-PP.
171. Courreges JP, Vilsboll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med. 2008;25:1129-1131.
172. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med. 2012. Sep;29:1115-1118.
173. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care. 2010;33:1028-1030.
174. Irace C, De Luca S, Shehaj E, et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res. 2012 Jun 25. [Epub ahead of print].
175. Rizzo M, Patti A, Di Bartolo V, Giglio R, Montalto G, Rizvi A. Effect of liraglutide on carotid intima-media thickness in patients with type 2 diabetes: a 4-month prospective study. American Diabetes Association 72nd Scientific Sessions; June 8-12, 2012; Philadelphia, PA [abstract 418-P].
176. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2011;33:1491-1499.
177. Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia Circ Cardiovasc Interv. 2012;5:288-295.
178. Nathanson D, Ullman B, Lofstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55:926-935.
179. U.S. National Institutes of Health. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. http://www.clinicaltrials.gov/ct2/show/NCT01144338?term=NCT01144338&ra nk=1. Accessed for verification October 25, 2012.
180. U.S. National Institutes of Health. Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results - a long term evaluation (LEADER®). http://www.clinicaltrials.gov/ct2/show/NCT0 1179048?term= NCT01179048&rank=1. Accessed for verification October 25, 2012.
181. Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1C, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. Diabetes. 2009;58(Suppl 1):162-OR.
182. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2012 Aug 3. [Epub ahead of print].
183. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.
184. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Prim Care Diabetes. 2011;6:41-6.
185. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract. 2012;18:17-25.
186. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734-743.
187. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132-138.
188. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883-889.
189. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163-1172.
190. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring). 2011;19:2310-2315.
191. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without prediabetes. Diabetes Care. 2010;33:1173-1175.
192. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide. Int J Obes (Lond). 2012;36:890.
193. Wadden T, Hollander P, Klein S, et al. Liraglutide provides weight maintenance and additional weight loss after low calorie diet-induced weight loss in obese subjects without diabetes: the SCALETM maintenance study. Diabetes. 2011;60(Suppl 1):1859-P.
194. Novo Nordisk. Study results - comparison of liraglutide versus placebo in weight loss maintenance in obese subjects: SCALE - maintenance. http://www.clinicaltrials.gov/ct2/show/study/NCT00781937?term=scale +liraglutide&rank=1§=Xf015. Accessed for verification October 25, 2012.
195. Dushay J, Gao C, Gopalakrishnan GS, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes Diabetes Care. 2012;35:4-11.
196. Kelly AS, Metzig AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring). 2012;20:364-370.
197. Vieta A, Badia X, Sacristan JA. A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus. Clin Ther. 2011;33:1225-1245.
198. U.S. Food and Drug Administration. FDA guidance for industry - patient-reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed for verification October 25, 2012.
199. Alberti G. The DAWN (diabetes attitude, wishes and needs) study. Pract Diabetes Int. 2002;19:22-24.
200. Skovlund S, Peyrot M, DAWN International Advisory Panel. The diabetes attitudes, wishes, and needs program: a new approach to improving outcomes of diabetes care. Diabetes Spectrum. 2005;18:136-142.
201. Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study Diabet Med. 2005;22:1379-1385.
202. Rubin RR, Peyrot M, Siminerio LM. Health care and patient-reported outcomes: Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study. Diabetes Care. 2006;29:1249-1255.
203. Jendle J, Torffvit O, Ridderstrale M, Lammert M, Ericsson A, Bogelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26:917-923.
204. Jendle J, Torffvit O, Ridderstrale M, Ericsson A, Nilsen B, Bogelund M. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. J Med Econ. 2012 Aug 1. [Epub ahead of print].
205. Kruger DF, Bode B, Spollett GR. Understanding GLP-1 analogs and enhancing patients success. Diabetes Educ. 2010;36(Suppl 3):44S-72S; quiz 73S-74S.
206. Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Pract. 2010;64:1402-1414.
207. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev. 2004;20:411-417.
208. Secnik Boye K, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes. 2006;4:80.
209. Bode BW, Testa MA, Magwire M, et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:604-612.
210. Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care. 2011;34:314-319.
211. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009;26:722-728.
212. Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. Diabet Med. 2011;28:715-723.